a nonsignificant trendP =0.054
After a median follow‐up period of 81 (48–113) months for the CABG group and 96 (53–115) months for the HCR group, there was a nonsignificant trend in survival in favor of HCR (CABG 85% versus HCR 96%; P =0.054) and no difference in freedom from any form of revascularization (CABG 92% versus HCR 91%; P =0.80).